VANCOUVER, BC – June 1, 2020 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) is pleased to announce that it intends to extend the term of 300,000 share purchase warrants (the “Warrants”). The original expiry date of the Warrants was two years from the date of the Company’s listing on the Canadian Securities Exchange. The Company proposes to extend the expiry date to October 12, 2022. In all other respects the terms of the Warrants will remain unchanged and in full force and effect.
The Warrants and the common shares issuable upon exercise of the Warrants are subject to a four month and a day hold period from the date of the issuance of the Warrants pursuant to applicable Canadian securities laws.
ON BEHALF OF THE BOARD
Chief Executive Officer
About Izotropic Corp.
Izotropic Corporation and its wholly owned U.S. operating subsidiary, Izotropic Imaging Corp. have been established to commercialize the next generation of breast imaging technology for early diagnosis of breast cancer. The Izotropic Breast CT Imaging System produces high resolution breast images in 3D. A single 10 second breast CT scan acquires approximately 500 images, without painful breast compression, providing radiologists with fully 3D viewing of the scanned breast. Mammography scanning requires compression of the breast between 2 imaging plates, resulting in 2D images.
The Company has the exclusive worldwide license from the University of California, Davis (UC Davis) to commercialize the technology developed by principal founder and Company director Dr. John M. Boone and researchers at UC Davis. The license includes all intellectual property, trade secrets, patents and patent-pending applications that are the foundation of the Company’s breast CT imaging platform.
Approximately $20 million in research funding and over 15 years of research and development have been invested in developing this groundbreaking breast CT imaging technology. Research includes a current, ongoing $2.9M U.S. clinical trial at UC Davis Medical Center.
The Company founders believe that this technology will be a disruptive entry to the market, overcoming many of the challenges faced by existing breast imaging modalities.